Regado Biosciences Inc (RGDO) 1.13 $RGDO
5 Stocks Ready to Break Out and Soar Higher
at The Street - Mon Oct 20, 9:24AM CDT
These stocks look ready to break out and trade higher from current levels.
VJET: 12.91 (-0.67), RWLK: 26.84 (-1.26), PLX: 2.35 (-0.01), NDLS: 22.26 (-0.61), RGDO: 1.13 (-0.02)
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Oct 15, 6:00AM CDT
Keep these under-$10 biotech stocks on your breakout trading radar.
ATNM: 7.15 (-0.08), RCPI: 0.28 (unch), RGDO: 1.13 (-0.02)
Regado Biosciences names Michael A. Metzger as CEO
M2 - Mon Oct 13, 3:05AM CDT
Biopharmaceutical company Regado Biosciences (NasdaqCM:RGDO) disclosed on Friday the addition of Michael A. Metzger to the additional post of chief executive officer plus as a member of its board of directors.
RGDO: 1.13 (-0.02)
Regado Biosciences Appoints Michael A. Metzger CEO
PR Newswire - Fri Oct 10, 6:30AM CDT
Regado Biosciences, Inc. (NASDAQ: RGDO), today announced the appointment of Michael A. Metzger, president of Regado, to the additional post of chief executive officer and as a member of the Board of Directors effective immediately. Mr. Metzger previously served as president and chief operating officer of Regado. He replaces David J. Mazzo, Ph.D., who has resigned from the company.
RGDO: 1.13 (-0.02)
CorMedix Files IND Application for Neutrolin in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 4:10PM CDT
CorMedix Inc. (CRMD) announced that it has filed an Investigational New Drug (IND) application to the FDA for Neutrolin.
CRMD: 1.75 (+0.09), CBM: 17.72 (-0.16), GILD: 105.37 (-1.30), RGDO: 1.13 (-0.02)
Regado Trims Workforce, Revamps Strategy on Trial Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 3:30PM CDT
Regado (RGDO) has reduced its work force by almost 60%.
MNK: 87.35 (-1.95), MDVN: 98.06 (+1.09), GILD: 105.37 (-1.30), RGDO: 1.13 (-0.02)
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Sep 26, 8:12AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
MACK: 8.42 (-0.26), BOTA: 2.46 (-0.01), RGDO: 1.13 (-0.02)
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma
PR Newswire - Fri Sep 26, 7:45AM CDT
The US markets on Thursday, September 25, 2014, declined with the Dow Jones Industrial Average finishing at 16,945.80, down 1.54% and the NASDAQ Composite closing at 4,466.75, down 1.94%. The S&P 500 ended the session 1.62% lower at 1,965.99. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index closed the day at 743.47, down 1.58%, whereas the index has advanced 4.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), Regado Biosciences Inc. (NASDAQ: RGDO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP). Free research on these five companies can be accessed at:
ACAD: 26.11 (-0.66), PCYC: 114.98 (-1.58), RPTP: 10.13 (-0.46), INCY: 52.62 (+0.18), RGDO: 1.13 (-0.02)
Market Maker Surveillance Report. IG, CNET, STV, AIXG, MDBX, RGDO, Winning Stocks With Lowest Price Friction For Thursday, September 25th 2014
M2 - Fri Sep 26, 3:29AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4456 companies with "abnormal" market making, 1102 companies with positive Friction Factors and 4256 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. IGI Laboratories Inc (NYSE:IG), Chinanet Online Holdings Inc (NASDAQ:CNET), China Digital Tv Holding Co Ltd (NYSE:STV), Aixtron SE (NASDAQ:AIXG), (OTC:MDBX), (NASDAQ:RGDO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
AIXG: 13.18 (-0.28), STV: 4.02 (unch), CNET: 2.09 (+0.04), IG: 9.03 (-0.33), RGDO: 1.13 (-0.02)
Seattle Genetics' Adcetris Positive in Durability Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:27PM CDT
Seattle Genetics, Inc. (SGEN) announced data from a two-year durability analysis of a phase I study on Adcetris for newly diagnosed mature T-cell lymphoma (MTCL).
GILD: 105.37 (-1.30), SGEN: 34.81 (-0.50), AMGN: 142.40 (-1.69), RGDO: 1.13 (-0.02)
Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 5:10PM CDT
Novavax, Inc. (NVAX) announced positive top-line data from a phase I/II study on influenza vaccine candidate, H7N9 VLP.
MDVN: 98.06 (+1.09), GILD: 105.38 (-1.29), NVAX: 4.89 (-0.10), RGDO: 1.13 (-0.02)
Regado Biosciences Announces Workforce Reduction and Provides Update on Strategic Direction
PR Newswire - Wed Sep 24, 3:53PM CDT
Regado Biosciences, Inc. (NASDAQ: RGDO), today announced a reduction of its workforce of approximately 60%, or 20 employees, across all operational sites. As a result of the workforce reduction, the company projects restructuring charges in the third and fourth quarter of 2014 of approximately $2 million in connection with one-time employee termination costs and facility shut down expenses. Regado expects that the reduction in workforce, coupled with the termination of expenses associated with its REGULATE-PCI clinical trial, will decrease annualized cash expenditures significantly.
RGDO: 1.13 (-0.02)
Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 1:50PM CDT
Merck KGaA (MKGAF) remains on track for its "Fit for 2018" program and discusses its plans regarding the immunology, oncology and immuno-oncology pipeline.
BIIB: 305.80 (-20.97), GILD: 105.38 (-1.29), RGDO: 1.13 (-0.02)
Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems
PR Newswire - Fri Sep 19, 8:55AM CDT
Biotech companies make announcements illustrating significant progress in medical technology, development of emerging drug systems and advanced Laboratory Instrumentation. Companies in focus today are: (OTC: PBIO), Benton, Dickinson and Company (NYSE: BDX), Thermo Fisher Scientific Inc. (NYSE: TMO), Regado Biosciences Inc. (NASDAQ: RGDO), Sangamo Biosciences Inc. (NASDAQ: SGMO) and Hologic Inc. (NASDAQ: HOLX)
BDX: 123.95 (+0.64), TMO: 112.90 (-5.32), SGMO: 10.39 (-0.13), HOLX: 24.43 (-0.33), RGDO: 1.13 (-0.02)
Avanir Pharmaceuticals Shoots Up on Positive AVP-923 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 2:50PM CDT
Avanir (AVNR) reported positive data on AVP-923.
AGN: 183.07 (-3.09), LCI: 44.53 (-0.43), AVNR: 11.70 (-0.09), RGDO: 1.13 (-0.02)
QLT Unveils Positive Retreatment Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 5:50PM CDT
QLT (QLTI) announced encouraging final data on QLT091001.
AGN: 183.07 (-3.09), QLTI: 4.00 (+0.01), AUXL: 31.10 (-0.02), RGDO: 1.13 (-0.02)
Will Allergan's Board Be Revamped to Aid Valeant Buyout? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:25PM CDT
Pershing Square submitted requests for a Special Meeting from stockholders owning 1.5% of Allergan (AGN) shares.
AGN: 183.07 (-3.09), VRX: 128.29 (-2.09), GILD: 105.38 (-1.29), RGDO: 1.13 (-0.02)
Alexion's Asfotase Alfa Gets Japanese Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:30PM CDT
Japan's MHLW granted orphan drug status to Alexion's (ALXN) asfotase alfa.
AGN: 183.07 (-3.09), ENDP: 63.68 (-0.05), ALXN: 172.38 (-2.10), RGDO: 1.13 (-0.02)
OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:00PM CDT
OncoMed Pharmaceuticals' (OMED) shares were up 5.7% with the FDA lifting the partial clinical hold on ipafricept for ovarian cancer, pancreatic cancer and liver cancer.
GILD: 105.38 (-1.29), OMED: 20.01 (+0.20), RGDO: 1.13 (-0.02)
Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:45PM CDT
Celgene's (CELG) Revlimid performed well in a late-stage study on NDMM.
GILD: 105.38 (-1.29), ILMN: 187.00 (+7.45), RGDO: 1.13 (-0.02), CELG: 94.10 (-0.87)
5 Stocks Ready to Break Out and Soar Higher
at The Street - Mon Oct 20, 9:24AM CDT
These stocks look ready to break out and trade higher from current levels.
VJET: 12.91 (-0.67), RWLK: 26.84 (-1.26), PLX: 2.35 (-0.01), NDLS: 22.26 (-0.61), RGDO: 1.13 (-0.02)
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Oct 15, 6:00AM CDT
Keep these under-$10 biotech stocks on your breakout trading radar.
ATNM: 7.15 (-0.08), RCPI: 0.28 (unch), RGDO: 1.13 (-0.02)
Regado Biosciences names Michael A. Metzger as CEO
M2 - Mon Oct 13, 3:05AM CDT
Biopharmaceutical company Regado Biosciences (NasdaqCM:RGDO) disclosed on Friday the addition of Michael A. Metzger to the additional post of chief executive officer plus as a member of its board of directors.
RGDO: 1.13 (-0.02)
Regado Biosciences Appoints Michael A. Metzger CEO
PR Newswire - Fri Oct 10, 6:30AM CDT
Regado Biosciences, Inc. (NASDAQ: RGDO), today announced the appointment of Michael A. Metzger, president of Regado, to the additional post of chief executive officer and as a member of the Board of Directors effective immediately. Mr. Metzger previously served as president and chief operating officer of Regado. He replaces David J. Mazzo, Ph.D., who has resigned from the company.
RGDO: 1.13 (-0.02)
CorMedix Files IND Application for Neutrolin in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 4:10PM CDT
CorMedix Inc. (CRMD) announced that it has filed an Investigational New Drug (IND) application to the FDA for Neutrolin.
CRMD: 1.75 (+0.09), CBM: 17.72 (-0.16), GILD: 105.37 (-1.30), RGDO: 1.13 (-0.02)
Regado Trims Workforce, Revamps Strategy on Trial Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 3:30PM CDT
Regado (RGDO) has reduced its work force by almost 60%.
MNK: 87.35 (-1.95), MDVN: 98.06 (+1.09), GILD: 105.37 (-1.30), RGDO: 1.13 (-0.02)
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Sep 26, 8:12AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
MACK: 8.42 (-0.26), BOTA: 2.46 (-0.01), RGDO: 1.13 (-0.02)
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma
PR Newswire - Fri Sep 26, 7:45AM CDT
The US markets on Thursday, September 25, 2014, declined with the Dow Jones Industrial Average finishing at 16,945.80, down 1.54% and the NASDAQ Composite closing at 4,466.75, down 1.94%. The S&P 500 ended the session 1.62% lower at 1,965.99. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index closed the day at 743.47, down 1.58%, whereas the index has advanced 4.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), Regado Biosciences Inc. (NASDAQ: RGDO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP). Free research on these five companies can be accessed at:
ACAD: 26.11 (-0.66), PCYC: 114.98 (-1.58), RPTP: 10.13 (-0.46), INCY: 52.62 (+0.18), RGDO: 1.13 (-0.02)
Market Maker Surveillance Report. IG, CNET, STV, AIXG, MDBX, RGDO, Winning Stocks With Lowest Price Friction For Thursday, September 25th 2014
M2 - Fri Sep 26, 3:29AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4456 companies with "abnormal" market making, 1102 companies with positive Friction Factors and 4256 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. IGI Laboratories Inc (NYSE:IG), Chinanet Online Holdings Inc (NASDAQ:CNET), China Digital Tv Holding Co Ltd (NYSE:STV), Aixtron SE (NASDAQ:AIXG), (OTC:MDBX), (NASDAQ:RGDO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
AIXG: 13.18 (-0.28), STV: 4.02 (unch), CNET: 2.09 (+0.04), IG: 9.03 (-0.33), RGDO: 1.13 (-0.02)
Seattle Genetics' Adcetris Positive in Durability Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:27PM CDT
Seattle Genetics, Inc. (SGEN) announced data from a two-year durability analysis of a phase I study on Adcetris for newly diagnosed mature T-cell lymphoma (MTCL).
GILD: 105.37 (-1.30), SGEN: 34.81 (-0.50), AMGN: 142.40 (-1.69), RGDO: 1.13 (-0.02)
Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 5:10PM CDT
Novavax, Inc. (NVAX) announced positive top-line data from a phase I/II study on influenza vaccine candidate, H7N9 VLP.
MDVN: 98.06 (+1.09), GILD: 105.38 (-1.29), NVAX: 4.89 (-0.10), RGDO: 1.13 (-0.02)
Regado Biosciences Announces Workforce Reduction and Provides Update on Strategic Direction
PR Newswire - Wed Sep 24, 3:53PM CDT
Regado Biosciences, Inc. (NASDAQ: RGDO), today announced a reduction of its workforce of approximately 60%, or 20 employees, across all operational sites. As a result of the workforce reduction, the company projects restructuring charges in the third and fourth quarter of 2014 of approximately $2 million in connection with one-time employee termination costs and facility shut down expenses. Regado expects that the reduction in workforce, coupled with the termination of expenses associated with its REGULATE-PCI clinical trial, will decrease annualized cash expenditures significantly.
RGDO: 1.13 (-0.02)
Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 1:50PM CDT
Merck KGaA (MKGAF) remains on track for its "Fit for 2018" program and discusses its plans regarding the immunology, oncology and immuno-oncology pipeline.
BIIB: 305.80 (-20.97), GILD: 105.38 (-1.29), RGDO: 1.13 (-0.02)
Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems
PR Newswire - Fri Sep 19, 8:55AM CDT
Biotech companies make announcements illustrating significant progress in medical technology, development of emerging drug systems and advanced Laboratory Instrumentation. Companies in focus today are: (OTC: PBIO), Benton, Dickinson and Company (NYSE: BDX), Thermo Fisher Scientific Inc. (NYSE: TMO), Regado Biosciences Inc. (NASDAQ: RGDO), Sangamo Biosciences Inc. (NASDAQ: SGMO) and Hologic Inc. (NASDAQ: HOLX)
BDX: 123.95 (+0.64), TMO: 112.90 (-5.32), SGMO: 10.39 (-0.13), HOLX: 24.43 (-0.33), RGDO: 1.13 (-0.02)
Avanir Pharmaceuticals Shoots Up on Positive AVP-923 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 2:50PM CDT
Avanir (AVNR) reported positive data on AVP-923.
AGN: 183.07 (-3.09), LCI: 44.53 (-0.43), AVNR: 11.70 (-0.09), RGDO: 1.13 (-0.02)
QLT Unveils Positive Retreatment Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 5:50PM CDT
QLT (QLTI) announced encouraging final data on QLT091001.
AGN: 183.07 (-3.09), QLTI: 4.00 (+0.01), AUXL: 31.10 (-0.02), RGDO: 1.13 (-0.02)
Will Allergan's Board Be Revamped to Aid Valeant Buyout? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:25PM CDT
Pershing Square submitted requests for a Special Meeting from stockholders owning 1.5% of Allergan (AGN) shares.
AGN: 183.07 (-3.09), VRX: 128.29 (-2.09), GILD: 105.38 (-1.29), RGDO: 1.13 (-0.02)
Alexion's Asfotase Alfa Gets Japanese Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:30PM CDT
Japan's MHLW granted orphan drug status to Alexion's (ALXN) asfotase alfa.
AGN: 183.07 (-3.09), ENDP: 63.68 (-0.05), ALXN: 172.38 (-2.10), RGDO: 1.13 (-0.02)
OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:00PM CDT
OncoMed Pharmaceuticals' (OMED) shares were up 5.7% with the FDA lifting the partial clinical hold on ipafricept for ovarian cancer, pancreatic cancer and liver cancer.
GILD: 105.38 (-1.29), OMED: 20.01 (+0.20), RGDO: 1.13 (-0.02)
Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:45PM CDT
Celgene's (CELG) Revlimid performed well in a late-stage study on NDMM.
GILD: 105.38 (-1.29), ILMN: 187.00 (+7.45), RGDO: 1.13 (-0.02), CELG: 94.10 (-0.87)
